Aurora, CO – According to filings with the U.S. Securities and Exchange Commission, Taiga Biotechnologies is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, James Kelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Taiga Biotechnologies

Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving blood stem cell transplantation. Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells. Taiga Biotechnologies, Inc.’s technology is centered around boosting the immune system to better fight disease.

To learn more about Taiga Biotechnologies, visit http://www.taigabiotech.com/

Contact:
James Kelly, Chief Financial Officer
720-859-3547
https://www.linkedin.com/in/jim-kelly-5439a84/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved